ColoPlex Biomarker Data Published in
Journal of Clinical Oncology
Novel blood-based biomarker candidates in screening for colorectal cancer.
Jason Lee Liggett, Mathias M Petersen, Jakob Kleif, Morten Rasmussen, Lars Nannestad Jørgensen, Jakob Benedict Seidelin, Mogens R. Madsen, Jesper Vilandt, Kåre Andersson Gotschalck, Lars M. Andersen, Ali Khalid, Berit Andersen, Ib Jarle Christensen, Herbert A. Fritsche, Eric S. Mayer, Christina Therkildsen
ABSTRACT
244
Background: Colorectal cancer (CRC) is the third most common cancer worldwide motivating national screening strategies utilizing fecal immunochemical tests (FIT). Blood-based biomarkers could be an alternative method to increase compliance in population-based screening programs for early detection of CRC. We aimed to identify new blood-based biomarkers that could be potential candidates for use in colorectal cancer screening. Methods: In a nested cohort study of 1967 FIT positive participants of the Danish CRC screening program serum levels of GDF-15, hepsin, IL-8, keratin1-10, L1CAM, MIA, monocyte MCP-1, NSE and OPG were measured using the Luminex xMAP immunoassay platform. Main outcomes were CRC vs non-CRC and CRC, high-risk adenomas (HRA) or medium-risk adenomas (MRA) vs low-risk adenomas (LRA) or clean colorectum. Odds ratios for associations between biomarker expressions and outcomes were calculated using logistic regression models and visualized by area under the receiver operating characteristic (ROC) curve (AUC). Analyses were made on the Luminex biomarkers alone and with addition of clinical and demographic information. Results: FIT-induced colonoscopies detected 240 CRCs and 625 HRA or MRA. Multivariate analyses using all biomarkers and age found hepsin, IL-8 and OPG significantly (p<0.001) associated in relation to the main outcome (CRC vs non-CRC) with odds ratios of 0.74 [0.59-0.92], 2.59 [2.12-3.15] and 0.90 [0.82-0.99], respectively. The full model using all biomarkers and age presented an AUC of 0.73 [0.70-0.77]. Conclusions: Changed serum levels of nine novel biomarkers seem to be potential predictors for early detection of CRC, especially hepsin, IL-8 and OPG.
See the multivariable analysis for the two main study outcomes including all nine biomarkers and age on the publication page in the Journal of Clinical Oncology, Volume 41, Issue 4 supp.
Press Release: ColoHealth Blood Test Offers a Simpler First Step in Colorectal Cancer Screening–Now Direct-to-Consumer
New Day Diagnostics today announced the launch of ColoHealth™, a groundbreaking blood test for colorectal cancer screening is now accessible to adults aged 50+ who are at average risk. This test offers a non-invasive alternative for individuals who are unwilling or...
Hepion Pharmaceuticals, New Day Diagnostics execute binding letter of intent
We’re honored to be featured in publications near and far, but there’s something especially meaningful about being recognized by our local and regional community. Thank you to Teknovation for helping share the news of our latest opportunity. Be sure to explore more of...
Press Release: Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other...
We’ve Been Busy, and the Press Has Noticed!
The past few months have been an exciting time for all of us at New Day Diagnostics. Since launching ColoHealth™, our blood-based colorectal cancer screening test, we've been honored to see our story featured in over 200 independent news articles across the country. ...
Press Release: ColoHealth™ Launches Nationwide to Expand Access to Colorectal Cancer Screening
ColoHealth is a blood test that detects alterations in DNA associated with colorectal cancer. It is not meant to replace a colonoscopy, but can inform patients who are unable or unwilling to do other forms of screening about their need for a colonoscopy.
Knoxville lab launches blood test for colorectal cancer screening across US: ‘Life mission’
By Daniel DassowKnoxville News SentinelKnoxville-based biotech company New Day Diagnostics launched its blood test screening for colorectal cancer nationwide after completing a year-long local pilot that helped patients reduce their risk for the deadly disease. Its...
Understanding CLIA and Its Crucial Role in Diagnostic Development
Clinical Laboratory Improvement Amendments (CLIA) is a set of regulations established by the United States government to ensure the quality, accuracy, and reliability of clinical laboratory testing. These regulations are vital for diagnostic development, as they...
Development of an algorithm combining blood-based biomarkers, fecal immunochemical test, and age for population-based colorectal cancer screening
Mathias M. Petersen, Jakob Kleif, Jason Liggett, Morten Rasmussen, Lars N. Jørgensen, Jesper Vilandt, Jakob B. Seidelin, Carla M.T. Beertsen, Annemieke C. Heijboer, Claudia Jaensch, Peter Bondeven, Kåre A. Gotschalck, Uffe Schou Løve, Susan H. Gawel, Berit Andersen,...
Press Release: Augurex and New Day Diagnostics Collaborate to Launch SPINEstat™, RevolutionizingEarly Diagnosis and Management of Ankylosing Spondylitis
By Augurex at www.augurex.com Vancouver, BC, Canada and Knoxville, TN, USA, 30 May 2024 – Augurex and New Day Diagnostics are excited to announce their collaboration to launch SPINEstat™, a first-of-its-kind multiplex biomarker assay that will transform the management...